Floatz logo

Axicabtagene Ciloleucel

Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma

Ruijin HospitalCell therapyPhase 4 / ApprovedActive
BBB
77/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
65/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma cohort.

Asset / SponsorPhaseRating
Anakinra
M.D. Anderson Cancer Center
Phase 2B
HUMAN FAECAL MATTER
City of Hope Medical Center
Phase 2CCC
Egfrt/19-28Z/Il-12 Car T-Lymphocytes
Roswell Park Cancer Institute
Phase 1CC

Same molecule, other indications

Axicabtagene Ciloleucel is also rated in:

B-cell Lymphoma RecurrentDormant
BBB
Indicative ·
76 / 100
View asset →
diffuse large B-cell lymphomaDormant
BBB
Indicative ·
75 / 100
View asset →
primary mediastinal large B-cell lymphomaDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →